CEVOLUTIONRecruiting

Cevostamab in combination with pomalidomide and dexamethasone compared with standard therapy in patients with previously treated multiple myeloma

Gender
Women and men
Age
18 years and older
Trial type
Interventional
Line of therapy
Relapsed / refractory
Phase
Phase III

What is this trial about?

is a malignant disease of the that can recur after initially successful treatment. The goal of the CEVOLUTION study is to investigate whether treatment with in combination with and is effective and well-tolerated in patients with previously treated multiple myeloma, compared with . Patients aged 18 and older with multiple myeloma who have already received one to three prior therapies, including at least two consecutive of an anti- drug or , are eligible to participate in this study.

Trial flow

Requirements

Diagnosis: Multiple Myeloma

Age: 18 years and older

Line of therapy: Rezidiv / primär refraktär

Key inclusion criteria: one to three lines of prior therapy that included at least two consecutive cycles of either of the following: A regimen containing an anti-CD38 therapy, a regimen containing lenalidomide

Allocation

Randomisierung

Treatment

Follow-up

60 months

Detailed description

Multiple myeloma is a type of and is a malignant disease of plasma cells, which originate from , a type of white blood cell. Normally, these cells produce that help the body fight off infections. When plasma cells multiply and become malignant, they develop into myeloma cells that proliferate uncontrollably in the bone marrow. These myeloma cells produce non-functional antibodies (M-proteins), disrupt normal blood cell production, and lead to bone loss. As a result, the disease can cause various symptoms, including bone pain, bone fractures, , and impaired kidney function. Patients with multiple myeloma are also more susceptible to infections. Multiple myeloma occurs predominantly in older adults; most patients are between 70 and 80 years old at the time of diagnosis. If the disease returns after an initially successful treatment (), several successive courses of treatment are often necessary. Standard therapy for previously treated multiple myeloma includes, among other things, antibodies targeting the surface markers CD38 and on cancer cells. These include the active ingredients , which targets CD38, and , which binds to the SLAMF7 protein on the surface of plasma cells. So-called , such as , are also used. These drugs inhibit the proteasome, a protein complex that breaks down proteins no longer needed by the body’s cells. When this breakdown is inhibited, the unwanted proteins accumulate in the cell and lead to cell death, which is intended to disrupt the growth of cancer cells. Dexamethasone is a —that is, a cortisone-like active ingredient—that is typically administered in combination with other medications for multiple myeloma and directly attacks the malignant myeloma cells. This study is investigating novel active ingredients such as cevostamab, a so-called that can bind to two different sites simultaneously. It binds to the protein on the surface of myeloma cells and to the body’s own —that is, immune system cells—so that the T cells are brought into close proximity to the cancer cells and can attack them. Pomalidomide belongs to a class of that are designed to inhibit the growth of myeloma cells while simultaneously stimulating the body’s own immune response against the cancer cells.

The goal of this Phase 3 study is to investigate whether treatment with cevostamab in combination with pomalidomide and dexamethasone is effective and well-tolerated compared with standard therapy in patients with previously treated multiple myeloma. Patients will be randomly assigned to one of two parallel treatment groups. In the , cevostamab is administered as an infusion together with pomalidomide as a tablet; dexamethasone is administered as a tablet or as an infusion, in each case prior to cevostamab. In the , patients receive standard therapy selected by the study physicians from approved combinations, which include daratumumab, elotuzumab, or carfilzomib (each in combination with pomalidomide and dexamethasone). The study is open-label (unblinded), meaning that both the patients and the study physicians know which treatment is being administered. The period is approximately 5 years.

Eligible participants are patients aged 18 and older with confirmed multiple myeloma who have already received one to three prior lines of therapy, including treatment with an anti-CD38 therapy or with lenalidomide.

Facts

  1. Disease:
  2. Cancer characteristics: previously treated (one to three prior lines of therapy, including anti- therapy or ), measurable disease
  3. What the study is investigating: in combination with and compared to
  4. Study objective: to investigate whether the combination of cevostamab, pomalidomide, and dexamethasone is effective and well-tolerated in patients with previously treated multiple myeloma
  5. Study duration: approximately 7 years (expected to run from 2026 to 2033)
  6. Study characteristics: Phase 3 study, , parallel groups, open-label (unblinded)

Trial sites

18 trial sites in Germany are listed. Find a site near you.

  • Universitätsklinikum Augsburg

    Stenglinstrasse 2, 86156 Augsburg

    Active, not recruiting
  • HELIOS Klinikum Bad Saarow

    Pieskower Strasse 33, 15526 Bad Saarow

    Recruiting
  • Charité – Universitätsmedizin Berlin

    Berlin

    Recruiting
  • Vivantes - Netzwerk fuer Gesundheit GmbH

    Dieffenbachstrasse 1/1, 10967 Berlin

    Status unknown
  • Vivantes Klinikum Am Urban Klinik für Innere Medizin Hämatologie und Onkologie

    10967 Berlin

    Recruiting
  • Universitätsklinikum Bonn

    Venusberg-Campus 1, 53127 Bonn

    Status unknown

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.